Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.allogene.com
Allogene Therapeutics News Releases
Get the latest updates from Allogene Therapeutics News Releases directly as they happen.
Follow now 100 followers
Latest posts
Last updated 4 days ago
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
4 months ago
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m...
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
4 months ago
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
4 months ago
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics...
Allogene Therapeutics Announces Planned CEO Succession
4 months ago
David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer...
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
about 2 months ago
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2...
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
about 2 months ago
FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s...
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
about 1 month ago
Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m...
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
about 1 month ago
Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent...
Allogene Therapeutics Announces Participation in September Investor Conference
12 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics...
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
10 days ago
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
6 months ago
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First...
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
6 months ago
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m...